DAX is currently on bullish momentum. At 17:30 EST on Wed 23 Dec, DAX is €13,587.20, 1.26% up since last session's close.
DAX Range
Concerning DAX's daily lows, it's 0% down from its trailing 24-hour low of €13,587.20
Over the last week, DAX's higher value was €13,747.60 and the lower value was €13,161.20.
Over the last month, DAX's higher value was €13,747.60 and the lower value was €13,037.20.
In relation to DAX's yearly highs and lows, it's 64.581% up from its 52-week low and 1.508% down from its 52-week high.
Last news about DAX
DAX tumbles on Covid-19 worries. According to Business Insider on Mon Dec 21, "The benchmark DAX plunged 248 points, or 1.9 percent, to 13,376 after declining 0.3 percent on Friday."
DAX rebounds on US stimulus aid. According to Business Insider on Tue Dec 22, "The benchmark DAX jumped 164 points, or 1.2 percent, to 13,410 after plunging as much as 2.8 percent the previous day."
DAX rises on brexit deal hopes. According to Business Insider on Wed Dec 23, "The benchmark DAX rose 74 points, or 0.6 percent, to 13,492 after rallying 1.3 percent in the previous session."
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
